These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32745811)

  • 1. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.
    Kaur N; Singh R; Dar Z; Bijarnia RK; Dhingra N; Kaur T
    Infect Genet Evol; 2021 Apr; 89():104490. PubMed ID: 32745811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.
    Silvas JA; Vasquez DM; Park JG; Chiem K; Allué-Guardia A; Garcia-Vilanova A; Platt RN; Miorin L; Kehrer T; Cupic A; Gonzalez-Reiche AS; Bakel HV; García-Sastre A; Anderson T; Torrelles JB; Ye C; Martinez-Sobrido L
    J Virol; 2021 Aug; 95(17):e0040221. PubMed ID: 34133899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study.
    Bhattacharya S; Banerjee A; Ray S
    Int J Biol Macromol; 2021 Mar; 172():74-81. PubMed ID: 33385461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection.
    Taubner B; Peredo-Wende R; Ramani A; Singh G; Strle K; Cady NC
    Microbiol Spectr; 2021 Oct; 9(2):e0089021. PubMed ID: 34585942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
    Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
    Baig AM; Khaleeq A; Syeda H
    J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging plasticity of SARS-CoV-2.
    McCormick KD; Jacobs JL; Mellors JW
    Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
    [No Abstract]   [Full Text] [Related]  

  • 10. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.
    Moradi-Kalbolandi S; Majidzadeh-A K; Abdolvahab MH; Jalili N; Farahmand L
    Probiotics Antimicrob Proteins; 2021 Oct; 13(5):1239-1253. PubMed ID: 33770348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
    Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
    Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms.
    Bayat M; Asemani Y; Najafi S
    Int Immunopharmacol; 2021 Aug; 97():107679. PubMed ID: 33930707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches.
    Marei HE; Althani A; Afifi N; Pozzoli G; Caceci T; Angelini F; Cenciarelli C
    Mol Biol Rep; 2021 Sep; 48(9):6513-6524. PubMed ID: 34398427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
    Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development.
    Mehmood I; Ijaz M; Ahmad S; Ahmed T; Bari A; Abro A; Allemailem KS; Almatroudi A; Tahir Ul Qamar M
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.